Effect of soy protein supplementation in patients with chronic hepatitis C: A randomized clinical trial

Table 5 Median values of biochemical tests in patients with hepatitis C virus at the beginning of monitoring and after protein supplementation

	IG-soy						CG-casein
		Baseline	12 wk					Baseline	12 wk
Exams	n	Median (iq r)	Median (iq r)	change	% change	P value1	n	Median (iq r)	Median (iq r)	change	% change	P value1
Total cholesterol (mg/dL)	80	160.0 (44.0)	153.0 (44.7)	-7.0	-7.37	0.05	80	149.0 (49.7)	152.0 (61.5)	+3.0	+2.01	0.63
HDL (mg/dL)	79	44.0 (15.5)	43.5 (15.2)	-0.5	-1.14	0.69	80	44.0 (14.2)	46.0 (17.0)	+2.0	+5.54	0.13
LDL (mg/dL)	78	90.0 (43.0)	84.5 (41.5)	-5.5	-6.11	0.03	80	90.5 (40.7)	89.5 (45.0)	-1.0	-1.10	0.66
AST (U/L)	80	52.0 (44.5)	49.5 (44.2)	-2.5	4.81	0.32	78	59.5 (40.7)	61.5 (40.5)	+2.0	+3.36	0.04
ALT (U/L)	76	73.5 (53.0)	64.0 (50.0)	-9.5	-12.92	0.006	78	76.5 (54.5)	73.0 (65.7)	-3.5	-4.57	0.48
γGT (U/L)	73	87.0 (114.0)	84.0 (107.0)	-3.0	-3.45	0.007	75	102.0 (118.0)	108.0 (120.5)	+6.0	+5.88	0.19
HOMA-IR	80	2.3 (2.6)	2.6 (2.2)	+0.3	+13.04	0.23	79	2.3 (2.2)	2.4 (2.7)	+0.1	+4.35	0.09

¹Paired analysis: Wilcoxon test (P < 0.05): Change in the group, the Bonferroni correction (P < 0.007). HDL: High density lipoprotein; LDL: Low density lipoprotein; AST: Aspartate aminotransferase; ALT: Alanine aminotransferase; γGT: Gamma glutamyl transferase; CG-casein: Control group-casein; HOMA-IR: Homeostasis model assessment index of insulin resistance; IG-soy: Intervention group-soy; iq r: Interquartile range; n < 80: When an examination was not performed.